A Better Understanding of Alzheimer's Disease Pathology by Incorporating Modifiable Risk Factors and Omics Data PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download A Better Understanding of Alzheimer's Disease Pathology by Incorporating Modifiable Risk Factors and Omics Data PDF full book. Access full book title A Better Understanding of Alzheimer's Disease Pathology by Incorporating Modifiable Risk Factors and Omics Data by Ruocheng Dong (Ph.D.). Download full books in PDF and EPUB format.
Author: Ruocheng Dong (Ph.D.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 128
Get Book Here
Book Description
The recent advancements of untargeted metabolomics and the strategy of metabolome-wide association study (MWAS) enable us to incorporate metabolomics data in different tissue, e.g., blood and cerebrospinal fluid (CSF), and open a window to study the biological mechanisms of Alzheimer's disease (AD), especially in the preclinical stage. Using longitudinal and multi-omics data from the Wisconsin Registry for Alzheimer's Prevention (WRAP) and Wisconsin Alzheimer's Disease Research Center (ADRC) cohorts, we investigated the relationships between plasma and CSF metabolites, modifiable risk factors, genomics, and AD endophenotypes. First of all, by integrating plasma metabolites, modifiable risk factors of AD, including the MIND diet, physical activity, smoking and caffeine intake, and AD endophenotypes, e.g., CSF biomarkers and cognitive functions, we improved our knowledge about the potential metabolic changes associated with modifiable risk factors and their relationship with AD pathology. Second, we identified several CSF metabolites, e.g., phospholipids and metabolic pathways associated with different AD pathologies, and confirmed the causal effect of some metabolites based on Mendelian randomization. Finally, calculating and evaluating the polygenic risk score (PRS) for AD and AD endophenotypes based on traditional and recently developed methods offers valuable insight into AD PRS research. The combination of PRS and MWAS presents an example of integrating multi-omics data and extending the application of PRS. In general, the findings from this dissertation provide a solid foundation for future investigations of omics, pathology, environment impact, and the discovery of biomarkers in AD research, therefore, to help the prevention, diagnosis, and ultimately the therapy of AD.
Author: Ruocheng Dong (Ph.D.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 128
Get Book Here
Book Description
The recent advancements of untargeted metabolomics and the strategy of metabolome-wide association study (MWAS) enable us to incorporate metabolomics data in different tissue, e.g., blood and cerebrospinal fluid (CSF), and open a window to study the biological mechanisms of Alzheimer's disease (AD), especially in the preclinical stage. Using longitudinal and multi-omics data from the Wisconsin Registry for Alzheimer's Prevention (WRAP) and Wisconsin Alzheimer's Disease Research Center (ADRC) cohorts, we investigated the relationships between plasma and CSF metabolites, modifiable risk factors, genomics, and AD endophenotypes. First of all, by integrating plasma metabolites, modifiable risk factors of AD, including the MIND diet, physical activity, smoking and caffeine intake, and AD endophenotypes, e.g., CSF biomarkers and cognitive functions, we improved our knowledge about the potential metabolic changes associated with modifiable risk factors and their relationship with AD pathology. Second, we identified several CSF metabolites, e.g., phospholipids and metabolic pathways associated with different AD pathologies, and confirmed the causal effect of some metabolites based on Mendelian randomization. Finally, calculating and evaluating the polygenic risk score (PRS) for AD and AD endophenotypes based on traditional and recently developed methods offers valuable insight into AD PRS research. The combination of PRS and MWAS presents an example of integrating multi-omics data and extending the application of PRS. In general, the findings from this dissertation provide a solid foundation for future investigations of omics, pathology, environment impact, and the discovery of biomarkers in AD research, therefore, to help the prevention, diagnosis, and ultimately the therapy of AD.
Author: Ruocheng Dong (Ph.D.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 0
Get Book Here
Book Description
The recent advancements of untargeted metabolomics and the strategy of metabolome-wide association study (MWAS) enable us to incorporate metabolomics data in different tissue, e.g., blood and cerebrospinal fluid (CSF), and open a window to study the biological mechanisms of Alzheimer's disease (AD), especially in the preclinical stage. Using longitudinal and multi-omics data from the Wisconsin Registry for Alzheimer's Prevention (WRAP) and Wisconsin Alzheimer's Disease Research Center (ADRC) cohorts, we investigated the relationships between plasma and CSF metabolites, modifiable risk factors, genomics, and AD endophenotypes. First of all, by integrating plasma metabolites, modifiable risk factors of AD, including the MIND diet, physical activity, smoking and caffeine intake, and AD endophenotypes, e.g., CSF biomarkers and cognitive functions, we improved our knowledge about the potential metabolic changes associated with modifiable risk factors and their relationship with AD pathology. Second, we identified several CSF metabolites, e.g., phospholipids and metabolic pathways associated with different AD pathologies, and confirmed the causal effect of some metabolites based on Mendelian randomization. Finally, calculating and evaluating the polygenic risk score (PRS) for AD and AD endophenotypes based on traditional and recently developed methods offers valuable insight into AD PRS research. The combination of PRS and MWAS presents an example of integrating multi-omics data and extending the application of PRS. In general, the findings from this dissertation provide a solid foundation for future investigations of omics, pathology, environment impact, and the discovery of biomarkers in AD research, therefore, to help the prevention, diagnosis, and ultimately the therapy of AD.
Author: Maria Teresa Ferretti
Publisher: Academic Press
ISBN: 012819345X
Category : Medical
Languages : en
Pages : 514
Get Book Here
Book Description
Sex and Gender Differences in Alzheimer’s Disease: The Women’s Brain Project offers for the first time a critical overview of the evidence documenting sex and gender differences in Alzheimer’s disease neurobiology, biomarkers, clinical presentation, treatment, clinical trials and their outcomes, and socioeconomic impact on both patients and caregivers. This knowledge is crucial for clinical development, digital health solutions, as well as social and psychological support to Alzheimer’s disease families, in the frame of a precision medicine approach to Alzheimer’s disease.This book brings together up-to-date findings from a variety of experts, covering basic neuroscience, epidemiology, diagnosis, treatment, clinical trials development, socioeconomic factors, and psychosocial support. Alzheimer’s disease, the most common form of dementia, remains an unmet medical need for the planet. Wide interpersonal variability in disease onset, presentation, and biomarker profile make Alzheimer’s a clinical challenge to neuroscientists, clinicians, and drug developers alike, resulting in huge management costs for health systems and society. Not only do women represent the majority of Alzheimer’s disease patients, but they also represent two-thirds of caregivers. Understanding sex and gender differences in Alzheimer’s disease will lead to novel insights into disease mechanisms, and will be crucial for personalized disease management strategies and solutions, involving both the patient and their family. Endorsements/Reviews: "There is a clear sex and gender gap in outcomes for brain health disorders like Alzheimer’s disease, with strikingly negative outcomes for women. This understanding calls for a more systematic way of approaching this issue of inequality. This book effectively highlights and frames inequalities in all areas across the translational spectrum from bench-to-bedside and from boardroom-to-policy and economics. Closing the Brain Health Gap will help economies create recovery and prepare our systems for future global shocks." Harris A. Eyre MBBS, PhD, co-lead, Neuroscience-inspired Policy Initiative, OECD and PRODEO Institute. Instructor in Brain Health Diplomacy, Global Brain Health Institute, UCSF and TCD. "Sex and Gender Differences in Alzheimer's disease is the most important title to emerge on Alzheimer's disease in recent years.This comprehensive, multidisciplinary book is a must read for anyone with a serious interest in dementia prevention, diagnosis, treatment, care, cure and research. Precision medicine is the future of healthcare and this book represents an incredible and necessary resource to guide practice, policy and research in light of the fact that Alzheimer's disease disproportionately affects women. The combination of contributions from the most eminent experts and the most up-to-date research makes this an invaluable resource for clinicians, care providers, academics, researchers and policy makers. Given the complex nature of dementia and the multiple factors that influence risk and disease trajectory the scope of the book is both impressive and important covering sex differences in neurobiological processes, sex and gender differences in clinical aspects and gender differences linked to socioeconomic factors relevant to Alzheimer's disease. If you work in Alzheimer's disease, or indeed other dementias, then Sex and Gender Differences in Alzheimer's disease is a must have for your bookshelf." -- Sabina Brennan, PhD., C.Psychol.,PsSI., National representative for Ireland on Alzheimer Disease International's Medical and Scientific Advisory Panel
Author: Leonardo Pantoni
Publisher: Cambridge University Press
ISBN: 1107031664
Category : Medical
Languages : en
Pages : 375
Get Book Here
Book Description
Up-to-date discussion of the etiology, diagnosis, treatment, and prevention of this common cause of stroke and cognitive impairment.
Author: Raul Delgado-Morales
Publisher: Springer
ISBN: 3319538896
Category : Science
Languages : en
Pages : 520
Get Book Here
Book Description
Epigenetic mechanisms (DNA modifications, histone alterations and non-coding RNAs) are crucial for transcriptional regulation and alterations of the “physiological epigenome” are increasingly associated with human diseases. During the last decade the emerging field of neuroepigenomics have started to impact tremendously in areas such learning and memory, addiction or neurodegeneration. This expert volume covers the role of epigenetic molecular mechanism in regulation of central nervous system’s function, one of the most exciting areas of contemporary molecular neuroscience. The book describes the current knowledge on the epigenetic basis of human disease covering the complete lifespan: from neurodevelopment/childhood (Rett Syndrome, Rubinstein-Taybi, autism), adolescence (eating disorders, drug addiction, anxiety), adulthood (depression, schizophrenia, amyotrophic lateral sclerosis, Huntington’s disease) and elderly (Alzheimer’s disease, Parkinson’s disease). The book also covers the three major players on neuroepigenomic mechanisms: histones alterations, DNA modifications and non-coding RNAs, their roles at the molecular and cellular level and the impact of their alterations on neuronal function and behavior. Finally, a special chapter on state-of-the-art technologies helps the reader not only to understand epigenetic driven changes in human cognition and diseases but also the methodology that will help to generate paradigm shifts on our understanding of brain function and the role of the neuroepigenome in human diseases.
Author: Thimmaiah Govindaraju
Publisher: Royal Society of Chemistry
ISBN: 1839162740
Category : Medical
Languages : en
Pages : 531
Get Book Here
Book Description
Alzheimer’s disease is an increasingly common form of dementia and despite rising interest in discovery of novel treatments and investigation into aetiology, there are no currently approved treatments that directly tackle the causes of the condition. Due to its multifactorial pathogenesis, current treatments are directed against symptoms and even precise diagnosis remains difficult as the majority of cases are diagnosed symptomatically and usually confirmed only by autopsy. Alzheimer’s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities provides a comprehensive overview from aetiology and neurochemistry to diagnosis, evaluation and management of Alzheimer's disease, and latest therapeutic approaches. Intended to provide an introduction to all aspects of the disease and latest developments, this book is ideal for students, postgraduates and researchers in neurochemistry, neurological drug discovery and Alzheimer’s disease.
Author: Hugh S. Markus
Publisher: Oxford Medical Publications
ISBN: 0198515863
Category : Medical
Languages : en
Pages : 362
Get Book Here
Book Description
Stroke is a major cause of death and the major cause of adult neurological disability in most of the world. Despite its importance on a population basis, research into the genetics of stroke has lagged behind that of many other disorders. However, the situation is now changing. Anincreasing number of single gene disorders causing stroke are being described, and there is growing evidence that polygenic factors are important in the risk of apparently "sporadic" stroke.Stroke Genetics provides an up-to-date review of the area, suitable for clinicians treating stroke patients, and both clinical and non-clinical researchers in the field of cerebrovascular disease. The full range of monogenic stroke disorders causing cerebrovascular disease, including ischaemicstroke, intracerebral haemorrhage, aneurysms and arteriovenous malformations, are covered. For each, clinical features, diagnosis, and genetics are described. Increasing evidence suggest that genetic factors are also important for the much more common multifactorial stroke; this evidence isreviewed along with the results of genetic studies in this area. Optimal and novel strategies for investigating multifactorial stroke, including the use of intermediate phenotypes such as intima-media thickness and MRI detected small vessel disease are reviewed. The book concludes by describing apractical approach to investigating patients with stroke for underlying genetic disorders. Also included is a list of useful websites.
Author: Philip V Peplow
Publisher: Royal Society of Chemistry
ISBN: 1788017811
Category : Science
Languages : en
Pages : 500
Get Book Here
Book Description
From pathology to treatment, MicroRNAs in Diseases and Disorders highlights the role of microRNAs (miRNAs) in the development and progression of a variety of diseases, including cancer, neurological disease, endocrine disease and autoimmune disease, and underscores the utilization of miRNA targets in the treatment of these conditions. Providing a comprehensive account, this book also includes the identification of miRNAs as diagnostic and prognostic biomarkers for disease, as well as evaluates translational value from clinical trials using synthesized and functionalized miRNA mimics and inhibitors. With a global contribution list and chapters from leading experts across the field, MicroRNAs in Diseases and Disorders is an invaluable reference to miRNA researchers and health professionals in a variety of disease areas in government, academia and industry. The book will also appeal to pharmaceutical and medicinal chemists with an interest in miRNA targeting therapeutics, as well as to advanced students in chemical biology and drug discovery.
Author: Adam Bohr
Publisher: Academic Press
ISBN: 0128184396
Category : Computers
Languages : en
Pages : 385
Get Book Here
Book Description
Artificial Intelligence (AI) in Healthcare is more than a comprehensive introduction to artificial intelligence as a tool in the generation and analysis of healthcare data. The book is split into two sections where the first section describes the current healthcare challenges and the rise of AI in this arena. The ten following chapters are written by specialists in each area, covering the whole healthcare ecosystem. First, the AI applications in drug design and drug development are presented followed by its applications in the field of cancer diagnostics, treatment and medical imaging. Subsequently, the application of AI in medical devices and surgery are covered as well as remote patient monitoring. Finally, the book dives into the topics of security, privacy, information sharing, health insurances and legal aspects of AI in healthcare. Highlights different data techniques in healthcare data analysis, including machine learning and data mining Illustrates different applications and challenges across the design, implementation and management of intelligent systems and healthcare data networks Includes applications and case studies across all areas of AI in healthcare data
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309475201
Category : Medical
Languages : en
Pages : 399
Get Book Here
Book Description
When is it appropriate to return individual research results to participants? The immense interest in this question has been fostered by the growing movement toward greater transparency and participant engagement in the research enterprise. Yet, the risks of returning individual research resultsâ€"such as results with unknown validityâ€"and the associated burdens on the research enterprise are competing considerations. Returning Individual Research Results to Participants reviews the current evidence on the benefits, harms, and costs of returning individual research results, while also considering the ethical, social, operational, and regulatory aspects of the practice. This report includes 12 recommendations directed to various stakeholdersâ€"investigators, sponsors, research institutions, institutional review boards (IRBs), regulators, and participantsâ€"and are designed to help (1) support decision making regarding the return of results on a study-by-study basis, (2) promote high-quality individual research results, (3) foster participant understanding of individual research results, and (4) revise and harmonize current regulations.
